SlideShare a Scribd company logo
The randomized physiologic
assessment of thrombus aspiration
in patients with ST-segment
elevation myocardial infarction trial
PATA-STEMI study
Dejan Orlic, MD on behalf of PATA STEMI
investigators
Clinical center of Serbia
Belgrade, Serbia
Potential conflicts of interest
Speaker's name: Dejan Orlic
 I do not have any potential conflict of interest
Background and aim
• Routine thrombus aspiration is superior to
conventional PPCI in terms of improved
myocardial perfusion in patients with STEMI
• However, myocardial perfusion after thrombus
aspiration has not been evaluated by a
quantitative, invasive method, such as determining
the index of microcirculatory resistance (IMR)
• Our aim was to assess impact of thrombus
aspiration on myocardial perfusion assessed by
IMR in patients presenting with first STEMI
Method
IMR= 63x0,20=12,6 U
CV Tmn res= 12,9 %
CV Tmn hyp= 7,9 %
Rmyo= ∆P/F= Pd-Pv/1/Tmn
F≈1/Tmn
Pv≈0 mmHg
IMR= Pd x Tmn
Fearon WF, Circ 2003
Per protocol
analysis
Manual thrombus
aspiration
Eliminate catheter
Predilatation or
Direct stenting
Primary endpoint = significant
decrease of IMR
Patients with first STEMI
≤12h from onset of chest pain
randomization 1:1
PATA STEMI – study design
IMR
Direct stenting
or predilatation
*Thrombus aspiration catheter did not cross the lesion site and did not aspirate thrombi.
Crossover to predilatation*
**TIMI 0 or 1, or residual thrombus grade 4, or multipli thrombi persisted after predilatation.
Crossover to aspiration**
Conventional
PPCI group
Thrombus
Aspiration group
Angio
Wiring of IRA
ST
Rescue PCI
Prior MI
Prior CABG
LMCA
AV block
CPR
COPD
Expected IMR in conventional PPCI* = 38±20 U
Expected reduction by TA = 26% (28±20 U)
Alfa error = 5%; Power 80%
Sample size to detect difference 128 patients
Sample size calculation
*Fearon W et al., JACC, 2008
PATA STEMI – patient flow
RANDOMIZATION 1:1
Thrombus aspiration
(N=60)
Conventional
PCI (N=62)Coronary wire
Thrombus
aspiration
(N=66)
Predilatation
(N=30)
Stent implantation (N=68)
Direct stenting (N=58)
PTCA (N=4) TA alone (N=4)
IMR (N=76) IMR (N=52)
Coronary angiography
Stent implantation (N=51)
Direct stenting (N=21)
PTCA (N=1)
Crossover to predilatation (N=0)
Crossover to aspiration (N=10)
Final angiogram N=128
ECG at 60 min N=128
Echo ≤24h N=127 and at 4 mo N=125
Gentle predilatation (N=6)
Thrombus aspiration Conventional P value
(N=76) (N=52)
Clinical characteristics
Age 59,0±11,0 59,9±11,2 0,88
Male 50 (64,9%) 38 (73,1%) 0,94
Body mass index 26,8±3,86 27,9±4,56 0,41
Diabetes 9 (11,8% ) 5 (9,6%) 0,78
Hypertension 39 (51,3%) 28 (53,8%) 0,86
Hypercholesterolemia 17 (22,9%) 14 (27,4%) 0,67
Total ischemic time, min 190 (140-300) 175 (120-260) 0,12
System delay*, min 100 (65-165) 105 (65-145) 0,62
Killip class II 4 (5,2%) 3 (3,9%) 0,5
Angiographic characteristics
LAD 31 (40,8%) 22 (42,3%) 0,9
TIMI flow grade
0 or 1 60 (78,9%) 41 (78,8%) 1
2 9 (11,8%) 6 (11,5%) 1
3 7 (9,2%) 5 (9,6%) 1
Thrombus length 10.5±7.48 7.04±4.81 0,014
Baseline characteristics
*time from the first medical contact to the first balloon inflation or aspiration.
Thrombus aspiration Conventional P value
(N=76) (N=52)
Procedural characteristics
Fluoroscopy time 13.2±7.76 8.9±5.00 0,005
GP IIbIIIa inhibitor 24 (31,6%) 10 (19,2%) 0,15
Stent implantation 68 (89,5%) 51 (98,1%) 0,08
Stent length, mm 21,2±5,4 21,5±5,1 0,72
TIMI flow grade after wire
0 or 1 39 (51,3%) 16 (30,8%) 0,029
2 17 (22,4%) 25 (48,1%) 0,004
3 20 (26,3%) 11 (21,1%) 0,54
TIMI after TA/predilatation
0 or 1 1 (1,4%) 2 (6,7%) 0,20
2 8 (10,8%) 2 (6,7%) 0,72
3 65 (87,8%) 26 (86,6%) 1
TIMI final
2 4 (5,3%) 2 (3,8%) 1
3 72 (94,7%) 50 (96,2%) 1
Periprocedural complications
Distal embolizations* 11 (14,5%) 8 (15,4%) 0,9
Side branch occlusion 1 (1,3%) 4 (7,7%) 0,16
Procedural characteristics
*3 pts with crossover had distal embolizations (10,5 vs 21,2, P=0,09).
Primary endpoint
index of microcirculatory resistance
CV Tmn rest 15,3±8,9%; CV Tmn hyp 15,1±8,1%
Intention-to-treat analysis: IMR 42,4±36,1 vs. 32,0±22,4 U, P=0,020
P=0,0082
RR 32%
Per-protocol analysis
Adjacent non-IRA IMR 22,0±11,2 U vs. contralateral non-IRA IMR 25,8±17,9 U, p=0,3
59.2
46.1
31.6
40.4
9.2
13.5
0% 20% 40% 60% 80% 100%
1
2
ST 70 ST 30-70 ST 30
21.1
30.8
36.8
42.3
42.1
26.9
0% 20% 40% 60% 80% 100%
1
2
MBG 0 or 1 MBG 2 MBG 3
.
. Conventional PCI
Thrombus
aspiration
Myocardial blush grade Resolution of ST-segment elevation
Percent of patients Percent of patients
MBG 0 or 1: RR 0,68 (95% CI 0,38 to 1,24; p=0,21) ST >70%: RR 1,28 (95% CI 0,91 to 1,82; p=0,16)
Angiographic and ECG signs of
myocardial reperfusion
Histopathological examination confirmed successful thrombus aspiration
in 90,8% of patients.
Echocardiographic analysis
LV ESV/BSA
Ml/m2
LV EDV/BSA
31,531,2
33,9
30,3
62,0 60,8
70,8 68,0
P=0,062
10,6%↓
P=0,22
P<0,0001
P<0,0001
P=0,4
LV ESV (ml); LV EDV (ml); BSA (m²)
Infarct size
Median CK max
U/L
Median AUC CK
46 027
35 442
23%↓
P=0,039
24%↓
P=0,046
2414
1843
Con PPCI: IQR 114 – 7310 U/L
TA: IQR 72 – 5765 U/L
Con PPCI: IQR 5760 – 159135 U/L
TA: IQR 1395 – 108222 U/L
Echocardiographic analysis
LV EF
%
WMSI
49,9 48,8 51,4
54,6
6,0%↑
P=0,19
P= 0,5
P<0,0001
1,43 1,47
1,30
1,42
8,5%↓
P=0,13
P=0,0019
P= 0,9
LV EF (%); LV WMSI = wall motion score index
U
Clinical FU at 9 months
%
MACCE rate at 9 months
MACCE (death, reMI, stroke, CHF or TVR): Con PPCI 3 deaths (2 sudden deaths=stent thrombosis possible
and 1 stroke). 1 reSTEMI (stent thrombosis definite, TVR), 3 CHF and 3 TVR.
TA 1 death (sudden death), 1 reSTEMI, 1 CHF and 4 TVR (2 TLR).
19,6
9,2
P=0,092
13,5
3,9
P=0,045
1,9
1,3
5,8
1,3
1,9*
5,8
1,3
5,3
5,8
*1 patient had CVI and death; CHF=congestive heart failure
Regression model on
log-transformed IMR
Thrombus aspiration is independent predictor of lower lMR
(36,11 U; 95%CI 30,74-42,41 vs. 27,14 U; 95%CI 23,79-30,95, P=0.0076).
32%
Parameter Estimate*
95%
Lower
Limit
95%
Upper
Limit
p-value
Aspiration vs. Con. PPCI 0,7515 0,610 0,926 0,0076
DBP 1,012 1,002 1,022 0,0166
CK max (per 1000 units) 1,0888 1,013 1,170 0,0213
Age 1,0169 1,008 1,026 0,0005
*Per increase of 1 unit of the covariate, the IMR increases with the estimate as a FACTOR
Conclusion
• Manual thrombus aspiration reduces
microcirculatory resistance indicating improved
myocardial perfusion compared to conventional PPCI
in patients with STEMI.
• At mid term clinical follow up, the rate of hard
adverse cardiac events is lower in thrombus
aspiration group compared to conventional PPCI
group.
• Further studies powered for clinical outcomes are
needed to confirm significance of our findings.
Cath Lab Staff
Dejan Orlic
Goran Stankovic
Branko Belelsin
Milan Dobric
Milorad Zivkovic
Miodrag Ostojic
Study investigators
Coronary
physiology
Dejan Orlic
Miodrag Ostojic
Branko Beleslin
Milan Dobric
ECG analysis
Vladan Vukcevic
Milorad Zivkovic
Dejan Orlic
Echo analysis
Milorad Tesic
Danijela Zamaklar
Histopathologic
analysis
Milica Borovic
Data monitoring
and analysis
Goran Stankovic
Dejan Milasinovic
Dejan Orlic
Angiographic
analysis
Sinisa Stojkovic
Vladan Vukcevic
Milan Nedeljkovic
Dejan Orlic
SPECT
Dragana Sobic-
Saranovic
Cardiology clinic, Institute for histology, Institute for nuclear medicine
Clinical center of Serbia, School of medicine, University of Belgrade
Back-up slides
Echocardiographic analysis
CSI volume
0,40 0,41 0,44 0,43
P=0,6
P=0,0082
P=0,0083
CSI = cardiac sphericity index
IMR and MACCE rate
%
MACCE rate at 9 months
12,7
3,1
P=0,045
Median IMR 30,7 U
15,9
10,9
P=0,41
• Consecutive patients aged > 18 years
• First STEMI (≥ 2 mm of ST-segment elevation in
≥ 2 contiguous leads)
• Total ischemic time <12h
• Hemodynamic stability
INCLUSION CRITERIA
• Rescue PCI
• Stent thrombosis
• Prior CABG
• CPC resuscitation
• Advanced AV block
• Severe COPD
• Distal LMCA stenosis (non-IRA)
EXCLUSION CRITERIA
PATA STEMI
Thrombus
Aspiration
N = 66
Conventional
PCI
N = 62
Crossover
N = 10
Thrombus
Aspiration
N = 76
Conventional
PCI
N = 52
Crossover to aspiration: TIMI 0 or 1 after balloon inflation or thrombus >2 vessel diameter
Primary Endpoint = significantly decreased index of microcirculatory resistance
Patients with first STEMI
≤12h from onset of chest pain
Randomization 1:1
Predilatation
N = 6
Background
IMR= 63x0,20=12,6 U
CV Tmn bas= 12,9 %
CV Tmn hyp= 7,9 %
Rmyo= ∆P/F= Pd-Pv/1/Tmn
F≈1/Tmn
Pv≈0 mmHg
IMR= Pd x Tmn
Tmean= 3 boluses of saline at room t injected
into coronary artery during max hyperemia.
Specific, reproducible measure of
coronary microcirculatory status
less subject to hemodynamic
variation (changes in heart rate,
blood pressure, and cardiac
contractility).
Primary endpoint
• significant decrease of IMR
End points
Secondary endpoints
• blush grade
• ST-segment resolution
• infarct size by enzyme release
• LV remodeling indices by echo
• MACCE rate at 9 months
Cath Lab Staff
Dejan Orlic
Branko Belelsin
Goran Stankovic
Milan Dobric
Milorad Zivkovic
Study investigators
Coronary
physiology
Dejan Orlic
Branko Beleslin
Milan Dobric
ECG analysis
Vladan Vukcevic
Milorad Zivkovic
Dejan Orlic
Echo analysis
Milorad Tesic
Danijela Zamaklar
Histopathologic
analysis
Milica Borovic
Data monitoring
and analysis
Dejan Orlic
Dejan Milasinovic
Goran Stankovic
Angiographic
analysis
Vladan Vukcevic
Sinisa Stojkovic
Milan Nedeljkovic
Dejan Orlic
SPECT
Dragana Sobic-
Saranovic
Cardiology clinic, Institute for histology, Institute for nuclear medicine
Clinical center of Serbia, School of medicine, University of Belgrade

More Related Content

What's hot

Kirtane AJ - AIMRADIAL 2014 - Bivalirudin anticoagulation
Kirtane AJ - AIMRADIAL 2014 - Bivalirudin anticoagulationKirtane AJ - AIMRADIAL 2014 - Bivalirudin anticoagulation
Kirtane AJ - AIMRADIAL 2014 - Bivalirudin anticoagulation
International Chair on Interventional Cardiology and Transradial Approach
 
STEMI – My Approach 2010
STEMI – My Approach 2010STEMI – My Approach 2010
STEMI – My Approach 2010ishakansari
 
Early reperfusion in myocardial infarction
Early reperfusion in myocardial infarctionEarly reperfusion in myocardial infarction
Early reperfusion in myocardial infarctioncardiositeindia
 
Non invasive guided gdt
Non invasive guided gdtNon invasive guided gdt
Non invasive guided gdt
Quang Hạ Trần
 
Thrombolysis vs PCI for STEMI
Thrombolysis vs PCI for STEMIThrombolysis vs PCI for STEMI
Thrombolysis vs PCI for STEMI
Junhao Koh
 
Lo mejor en cardiopatía isquémica e intervencionismo
Lo mejor en cardiopatía isquémica e intervencionismoLo mejor en cardiopatía isquémica e intervencionismo
Lo mejor en cardiopatía isquémica e intervencionismo
Sociedad Española de Cardiología
 
Romagnoli E - AIMRADIAL 2013 - Radial and IABP
Romagnoli E - AIMRADIAL 2013 - Radial and IABPRomagnoli E - AIMRADIAL 2013 - Radial and IABP
Ablation ou traitement pharmacologique pour la FA : quelles stratégie à suivr...
Ablation ou traitement pharmacologique pour la FA : quelles stratégie à suivr...Ablation ou traitement pharmacologique pour la FA : quelles stratégie à suivr...
Ablation ou traitement pharmacologique pour la FA : quelles stratégie à suivr...
Brussels Heart Center
 
Mann T 201111
Mann T 201111Mann T 201111
Nuclear cardiology
Nuclear cardiologyNuclear cardiology
Nuclear cardiology
SGPGI, lucknow
 
Linee guida e timing chirurgico insufficienza aortica
Linee guida e timing chirurgico insufficienza aorticaLinee guida e timing chirurgico insufficienza aortica
Linee guida e timing chirurgico insufficienza aortica
ICARDIOLOGI
 
Fernando alfonso isr sec-2015
Fernando alfonso isr sec-2015Fernando alfonso isr sec-2015
Lo mejor en insuficiencia cardiaca. #postACC16.
Lo mejor en insuficiencia cardiaca. #postACC16.Lo mejor en insuficiencia cardiaca. #postACC16.
Lo mejor en insuficiencia cardiaca. #postACC16.
Sociedad Española de Cardiología
 
Cardiogenic shock following acute MI
Cardiogenic shock following acute MICardiogenic shock following acute MI
Cardiogenic shock following acute MI
Dr. Lokesh Khandelwal
 
Presenter Disclosure Information
Presenter Disclosure InformationPresenter Disclosure Information
Presenter Disclosure Information
drucsamal
 
Pe final
Pe finalPe final
Pe final
Frank Meissner
 
Management of Massive & Submassive Pulmonary Embolism
Management of Massive & Submassive Pulmonary EmbolismManagement of Massive & Submassive Pulmonary Embolism
Management of Massive & Submassive Pulmonary Embolism
Sun Yai-Cheng
 
Guzman L - AIMRADIAL 2014 - Radiation exposure
Guzman L - AIMRADIAL 2014 - Radiation exposureGuzman L - AIMRADIAL 2014 - Radiation exposure
Appropriteness Criteria for Coronary Revascularization
Appropriteness Criteria for Coronary RevascularizationAppropriteness Criteria for Coronary Revascularization
Appropriteness Criteria for Coronary Revascularization
Lalit Kapoor
 

What's hot (20)

Kirtane AJ - AIMRADIAL 2014 - Bivalirudin anticoagulation
Kirtane AJ - AIMRADIAL 2014 - Bivalirudin anticoagulationKirtane AJ - AIMRADIAL 2014 - Bivalirudin anticoagulation
Kirtane AJ - AIMRADIAL 2014 - Bivalirudin anticoagulation
 
STEMI – My Approach 2010
STEMI – My Approach 2010STEMI – My Approach 2010
STEMI – My Approach 2010
 
Early reperfusion in myocardial infarction
Early reperfusion in myocardial infarctionEarly reperfusion in myocardial infarction
Early reperfusion in myocardial infarction
 
Non invasive guided gdt
Non invasive guided gdtNon invasive guided gdt
Non invasive guided gdt
 
Thrombolysis vs PCI for STEMI
Thrombolysis vs PCI for STEMIThrombolysis vs PCI for STEMI
Thrombolysis vs PCI for STEMI
 
Lo mejor en cardiopatía isquémica e intervencionismo
Lo mejor en cardiopatía isquémica e intervencionismoLo mejor en cardiopatía isquémica e intervencionismo
Lo mejor en cardiopatía isquémica e intervencionismo
 
Romagnoli E - AIMRADIAL 2013 - Radial and IABP
Romagnoli E - AIMRADIAL 2013 - Radial and IABPRomagnoli E - AIMRADIAL 2013 - Radial and IABP
Romagnoli E - AIMRADIAL 2013 - Radial and IABP
 
Primary angioplasty
Primary angioplastyPrimary angioplasty
Primary angioplasty
 
Ablation ou traitement pharmacologique pour la FA : quelles stratégie à suivr...
Ablation ou traitement pharmacologique pour la FA : quelles stratégie à suivr...Ablation ou traitement pharmacologique pour la FA : quelles stratégie à suivr...
Ablation ou traitement pharmacologique pour la FA : quelles stratégie à suivr...
 
Mann T 201111
Mann T 201111Mann T 201111
Mann T 201111
 
Nuclear cardiology
Nuclear cardiologyNuclear cardiology
Nuclear cardiology
 
Linee guida e timing chirurgico insufficienza aortica
Linee guida e timing chirurgico insufficienza aorticaLinee guida e timing chirurgico insufficienza aortica
Linee guida e timing chirurgico insufficienza aortica
 
Fernando alfonso isr sec-2015
Fernando alfonso isr sec-2015Fernando alfonso isr sec-2015
Fernando alfonso isr sec-2015
 
Lo mejor en insuficiencia cardiaca. #postACC16.
Lo mejor en insuficiencia cardiaca. #postACC16.Lo mejor en insuficiencia cardiaca. #postACC16.
Lo mejor en insuficiencia cardiaca. #postACC16.
 
Cardiogenic shock following acute MI
Cardiogenic shock following acute MICardiogenic shock following acute MI
Cardiogenic shock following acute MI
 
Presenter Disclosure Information
Presenter Disclosure InformationPresenter Disclosure Information
Presenter Disclosure Information
 
Pe final
Pe finalPe final
Pe final
 
Management of Massive & Submassive Pulmonary Embolism
Management of Massive & Submassive Pulmonary EmbolismManagement of Massive & Submassive Pulmonary Embolism
Management of Massive & Submassive Pulmonary Embolism
 
Guzman L - AIMRADIAL 2014 - Radiation exposure
Guzman L - AIMRADIAL 2014 - Radiation exposureGuzman L - AIMRADIAL 2014 - Radiation exposure
Guzman L - AIMRADIAL 2014 - Radiation exposure
 
Appropriteness Criteria for Coronary Revascularization
Appropriteness Criteria for Coronary RevascularizationAppropriteness Criteria for Coronary Revascularization
Appropriteness Criteria for Coronary Revascularization
 

Similar to Tromboaspiración: resistencia de la microcirculación

Fu Q - AIMRADIAL 2014 - Left vs right radial approach
Fu Q - AIMRADIAL 2014 - Left vs right radial approachFu Q - AIMRADIAL 2014 - Left vs right radial approach
Fu Q - AIMRADIAL 2014 - Left vs right radial approach
International Chair on Interventional Cardiology and Transradial Approach
 
Thromboectomy trial
Thromboectomy trialThromboectomy trial
Euro CTO Club – The Euro CTO trial
Euro CTO Club – The Euro CTO trialEuro CTO Club – The Euro CTO trial
Euro CTO Club – The Euro CTO trial
Euro CTO Club
 
Expanding Role of Rivaroxaban Master .pptx
Expanding Role of Rivaroxaban Master .pptxExpanding Role of Rivaroxaban Master .pptx
Expanding Role of Rivaroxaban Master .pptx
AhsanRaza759717
 
Jnuc 2014 f beygui final
Jnuc 2014 f beygui finalJnuc 2014 f beygui final
Jnuc 2014 f beygui final
Nicolas Peschanski, MD, PhD
 
Tavi 2014
Tavi 2014Tavi 2014
Tavi 2014
DrMedhat Soliman
 
TAVI 2013: Revisión y perspectivas futuras
TAVI 2013: Revisión y perspectivas futurasTAVI 2013: Revisión y perspectivas futuras
TAVI 2013: Revisión y perspectivas futuras
CardioTeca
 
09 Cohen aimradial20170922 Ventricular support
09 Cohen aimradial20170922 Ventricular support09 Cohen aimradial20170922 Ventricular support
20 años de Angioplastia Primaria para el tratamiento del Infarto. Experiencia...
20 años de Angioplastia Primaria para el tratamiento del Infarto. Experiencia...20 años de Angioplastia Primaria para el tratamiento del Infarto. Experiencia...
20 años de Angioplastia Primaria para el tratamiento del Infarto. Experiencia...
SHCI - Sección de Hemodinámica y Cardiología Intervencionista
 
TRACER trial - Summary & Results
TRACER trial - Summary & ResultsTRACER trial - Summary & Results
TRACER trial - Summary & Results
theheart.org
 
La estimulación sin cables: resultados a medio plazo
La estimulación sin cables: resultados a medio plazoLa estimulación sin cables: resultados a medio plazo
La estimulación sin cables: resultados a medio plazo
Sociedad Española de Cardiología
 
Current Guidelines of Myocardial Revascularisation Patients with Stable Angin...
Current Guidelines of Myocardial Revascularisation Patients with Stable Angin...Current Guidelines of Myocardial Revascularisation Patients with Stable Angin...
Current Guidelines of Myocardial Revascularisation Patients with Stable Angin...
Chaichuk Sergiy
 
Foro Epic _ Oclusión Crónica Total (CTO): Intervención Coronaria Percutánea (...
Foro Epic _ Oclusión Crónica Total (CTO): Intervención Coronaria Percutánea (...Foro Epic _ Oclusión Crónica Total (CTO): Intervención Coronaria Percutánea (...
Foro Epic _ Oclusión Crónica Total (CTO): Intervención Coronaria Percutánea (...
Foro Epic
 
Dharma S - AIMRADIAL 2014 - Nitroglycerin and radial artery occlusion
 Dharma S - AIMRADIAL 2014 - Nitroglycerin and radial artery occlusion Dharma S - AIMRADIAL 2014 - Nitroglycerin and radial artery occlusion
Dharma S - AIMRADIAL 2014 - Nitroglycerin and radial artery occlusion
International Chair on Interventional Cardiology and Transradial Approach
 
Asaio 2017: Predicting Right Ventricular Failure in CF-LVAD Era.
Asaio 2017: Predicting Right Ventricular Failure in CF-LVAD Era.Asaio 2017: Predicting Right Ventricular Failure in CF-LVAD Era.
Asaio 2017: Predicting Right Ventricular Failure in CF-LVAD Era.
Cristiano Amarelli
 
Stroke update 2011
Stroke update 2011Stroke update 2011
Stroke update 2011taem
 
Practice Intersection: How I Approach Thrombus in My Daily Clinical Practice
Practice Intersection: How I Approach Thrombus in My Daily Clinical Practice Practice Intersection: How I Approach Thrombus in My Daily Clinical Practice
Practice Intersection: How I Approach Thrombus in My Daily Clinical Practice
Sociedad Latinoamericana de Cardiología Intervencionista
 

Similar to Tromboaspiración: resistencia de la microcirculación (20)

Fu Q - AIMRADIAL 2014 - Left vs right radial approach
Fu Q - AIMRADIAL 2014 - Left vs right radial approachFu Q - AIMRADIAL 2014 - Left vs right radial approach
Fu Q - AIMRADIAL 2014 - Left vs right radial approach
 
Thromboectomy trial
Thromboectomy trialThromboectomy trial
Thromboectomy trial
 
Euro CTO Club – The Euro CTO trial
Euro CTO Club – The Euro CTO trialEuro CTO Club – The Euro CTO trial
Euro CTO Club – The Euro CTO trial
 
Expanding Role of Rivaroxaban Master .pptx
Expanding Role of Rivaroxaban Master .pptxExpanding Role of Rivaroxaban Master .pptx
Expanding Role of Rivaroxaban Master .pptx
 
Jnuc 2014 f beygui final
Jnuc 2014 f beygui finalJnuc 2014 f beygui final
Jnuc 2014 f beygui final
 
Tavi 2014
Tavi 2014Tavi 2014
Tavi 2014
 
TAVI 2013: Revisión y perspectivas futuras
TAVI 2013: Revisión y perspectivas futurasTAVI 2013: Revisión y perspectivas futuras
TAVI 2013: Revisión y perspectivas futuras
 
Sort out iii
Sort out iiiSort out iii
Sort out iii
 
09 Cohen aimradial20170922 Ventricular support
09 Cohen aimradial20170922 Ventricular support09 Cohen aimradial20170922 Ventricular support
09 Cohen aimradial20170922 Ventricular support
 
20 años de Angioplastia Primaria para el tratamiento del Infarto. Experiencia...
20 años de Angioplastia Primaria para el tratamiento del Infarto. Experiencia...20 años de Angioplastia Primaria para el tratamiento del Infarto. Experiencia...
20 años de Angioplastia Primaria para el tratamiento del Infarto. Experiencia...
 
TRACER trial - Summary & Results
TRACER trial - Summary & ResultsTRACER trial - Summary & Results
TRACER trial - Summary & Results
 
La estimulación sin cables: resultados a medio plazo
La estimulación sin cables: resultados a medio plazoLa estimulación sin cables: resultados a medio plazo
La estimulación sin cables: resultados a medio plazo
 
Current Guidelines of Myocardial Revascularisation Patients with Stable Angin...
Current Guidelines of Myocardial Revascularisation Patients with Stable Angin...Current Guidelines of Myocardial Revascularisation Patients with Stable Angin...
Current Guidelines of Myocardial Revascularisation Patients with Stable Angin...
 
Wivon
WivonWivon
Wivon
 
Foro Epic _ Oclusión Crónica Total (CTO): Intervención Coronaria Percutánea (...
Foro Epic _ Oclusión Crónica Total (CTO): Intervención Coronaria Percutánea (...Foro Epic _ Oclusión Crónica Total (CTO): Intervención Coronaria Percutánea (...
Foro Epic _ Oclusión Crónica Total (CTO): Intervención Coronaria Percutánea (...
 
Dharma S - AIMRADIAL 2014 - Nitroglycerin and radial artery occlusion
 Dharma S - AIMRADIAL 2014 - Nitroglycerin and radial artery occlusion Dharma S - AIMRADIAL 2014 - Nitroglycerin and radial artery occlusion
Dharma S - AIMRADIAL 2014 - Nitroglycerin and radial artery occlusion
 
Asaio 2017: Predicting Right Ventricular Failure in CF-LVAD Era.
Asaio 2017: Predicting Right Ventricular Failure in CF-LVAD Era.Asaio 2017: Predicting Right Ventricular Failure in CF-LVAD Era.
Asaio 2017: Predicting Right Ventricular Failure in CF-LVAD Era.
 
Stroke update 2011
Stroke update 2011Stroke update 2011
Stroke update 2011
 
Practice Intersection: How I Approach Thrombus in My Daily Clinical Practice
Practice Intersection: How I Approach Thrombus in My Daily Clinical Practice Practice Intersection: How I Approach Thrombus in My Daily Clinical Practice
Practice Intersection: How I Approach Thrombus in My Daily Clinical Practice
 
Detecting acute coronary syndrome
Detecting acute coronary syndromeDetecting acute coronary syndrome
Detecting acute coronary syndrome
 

More from Sociedad Latinoamericana de Cardiología Intervencionista

CENTURY: resultados clínicos del nuevo stent liberador de sirolimus y polímer...
CENTURY: resultados clínicos del nuevo stent liberador de sirolimus y polímer...CENTURY: resultados clínicos del nuevo stent liberador de sirolimus y polímer...
CENTURY: resultados clínicos del nuevo stent liberador de sirolimus y polímer...
Sociedad Latinoamericana de Cardiología Intervencionista
 
ELISA 3: estrategia invasiva precoz vs tardía en pacientes sin supra desnivel...
ELISA 3: estrategia invasiva precoz vs tardía en pacientes sin supra desnivel...ELISA 3: estrategia invasiva precoz vs tardía en pacientes sin supra desnivel...
ELISA 3: estrategia invasiva precoz vs tardía en pacientes sin supra desnivel...
Sociedad Latinoamericana de Cardiología Intervencionista
 
DEFLECT I: dispositivo de protección cerebral en TAVI
DEFLECT I: dispositivo de protección cerebral en TAVIDEFLECT I: dispositivo de protección cerebral en TAVI
DEFLECT I: dispositivo de protección cerebral en TAVI
Sociedad Latinoamericana de Cardiología Intervencionista
 
POLAR ACS: plataforma bio absorbible en síndromes coronarios agudos
POLAR ACS: plataforma bio absorbible en síndromes coronarios agudosPOLAR ACS: plataforma bio absorbible en síndromes coronarios agudos
POLAR ACS: plataforma bio absorbible en síndromes coronarios agudos
Sociedad Latinoamericana de Cardiología Intervencionista
 
ELISA 3: estrategia invasiva precoz vs tardía en pacientes sin supra desnivel...
ELISA 3: estrategia invasiva precoz vs tardía en pacientes sin supra desnivel...ELISA 3: estrategia invasiva precoz vs tardía en pacientes sin supra desnivel...
ELISA 3: estrategia invasiva precoz vs tardía en pacientes sin supra desnivel...
Sociedad Latinoamericana de Cardiología Intervencionista
 
THRIVE: La niacina / laropiprant de liberación prolongada. Beneficio cardiova...
THRIVE: La niacina / laropiprant de liberación prolongada. Beneficio cardiova...THRIVE: La niacina / laropiprant de liberación prolongada. Beneficio cardiova...
THRIVE: La niacina / laropiprant de liberación prolongada. Beneficio cardiova...
Sociedad Latinoamericana de Cardiología Intervencionista
 
RELAX: Inhibidor de la fosfodiesterasa-5. Insuficiencia cardiaca con función ...
RELAX: Inhibidor de la fosfodiesterasa-5. Insuficiencia cardiaca con función ...RELAX: Inhibidor de la fosfodiesterasa-5. Insuficiencia cardiaca con función ...
RELAX: Inhibidor de la fosfodiesterasa-5. Insuficiencia cardiaca con función ...
Sociedad Latinoamericana de Cardiología Intervencionista
 
Reestenosis intrastent farmacológico con balón farmacológico
Reestenosis intrastent farmacológico con balón farmacológico Reestenosis intrastent farmacológico con balón farmacológico
Reestenosis intrastent farmacológico con balón farmacológico
Sociedad Latinoamericana de Cardiología Intervencionista
 
Stent liberador de sirolimus vs everolimus en bifurcaciones
Stent liberador de sirolimus vs everolimus en bifurcacionesStent liberador de sirolimus vs everolimus en bifurcaciones
Stent liberador de sirolimus vs everolimus en bifurcaciones
Sociedad Latinoamericana de Cardiología Intervencionista
 
¿Qué métodos han confirmado su eficacia para prevenir la nefropatía inducida ...
¿Qué métodos han confirmado su eficacia para prevenir la nefropatía inducida ...¿Qué métodos han confirmado su eficacia para prevenir la nefropatía inducida ...
¿Qué métodos han confirmado su eficacia para prevenir la nefropatía inducida ...
Sociedad Latinoamericana de Cardiología Intervencionista
 
BVS for BTK
BVS for BTKBVS for BTK
Antiplaquetarios en el síndrome coronario agudo
Antiplaquetarios en el síndrome coronario agudoAntiplaquetarios en el síndrome coronario agudo
Antiplaquetarios en el síndrome coronario agudo
Sociedad Latinoamericana de Cardiología Intervencionista
 
Polymer-Free DES
Polymer-Free DESPolymer-Free DES
Drug-Eluting Stents for Multivessel PCI
Drug-Eluting Stents for Multivessel PCIDrug-Eluting Stents for Multivessel PCI
Drug-Eluting Stents for Multivessel PCI
Sociedad Latinoamericana de Cardiología Intervencionista
 
The Effect of Timing of Stem Cell Delivery Following Acute Myocardial Infarct...
The Effect of Timing of Stem Cell Delivery Following Acute Myocardial Infarct...The Effect of Timing of Stem Cell Delivery Following Acute Myocardial Infarct...
The Effect of Timing of Stem Cell Delivery Following Acute Myocardial Infarct...
Sociedad Latinoamericana de Cardiología Intervencionista
 
Pilot Trial of Two Levels of Hypothermia in Comatose Survivors from Out-of-Ho...
Pilot Trial of Two Levels of Hypothermia in Comatose Survivors from Out-of-Ho...Pilot Trial of Two Levels of Hypothermia in Comatose Survivors from Out-of-Ho...
Pilot Trial of Two Levels of Hypothermia in Comatose Survivors from Out-of-Ho...
Sociedad Latinoamericana de Cardiología Intervencionista
 
Off-pump versus in-pump CABG in high-risk patients
Off-pump versus in-pump CABG in high-risk patientsOff-pump versus in-pump CABG in high-risk patients
Off-pump versus in-pump CABG in high-risk patients
Sociedad Latinoamericana de Cardiología Intervencionista
 
Posible beneficio de la esplerenona en pacientes con infarto agudo de miocard...
Posible beneficio de la esplerenona en pacientes con infarto agudo de miocard...Posible beneficio de la esplerenona en pacientes con infarto agudo de miocard...
Posible beneficio de la esplerenona en pacientes con infarto agudo de miocard...
Sociedad Latinoamericana de Cardiología Intervencionista
 
Cangrelor compared with clopidogrel improves efficiency without increasing bl...
Cangrelor compared with clopidogrel improves efficiency without increasing bl...Cangrelor compared with clopidogrel improves efficiency without increasing bl...
Cangrelor compared with clopidogrel improves efficiency without increasing bl...
Sociedad Latinoamericana de Cardiología Intervencionista
 
Rosuvastatina disminuye la incidencia de nefropatía por contraste en paciente...
Rosuvastatina disminuye la incidencia de nefropatía por contraste en paciente...Rosuvastatina disminuye la incidencia de nefropatía por contraste en paciente...
Rosuvastatina disminuye la incidencia de nefropatía por contraste en paciente...
Sociedad Latinoamericana de Cardiología Intervencionista
 

More from Sociedad Latinoamericana de Cardiología Intervencionista (20)

CENTURY: resultados clínicos del nuevo stent liberador de sirolimus y polímer...
CENTURY: resultados clínicos del nuevo stent liberador de sirolimus y polímer...CENTURY: resultados clínicos del nuevo stent liberador de sirolimus y polímer...
CENTURY: resultados clínicos del nuevo stent liberador de sirolimus y polímer...
 
ELISA 3: estrategia invasiva precoz vs tardía en pacientes sin supra desnivel...
ELISA 3: estrategia invasiva precoz vs tardía en pacientes sin supra desnivel...ELISA 3: estrategia invasiva precoz vs tardía en pacientes sin supra desnivel...
ELISA 3: estrategia invasiva precoz vs tardía en pacientes sin supra desnivel...
 
DEFLECT I: dispositivo de protección cerebral en TAVI
DEFLECT I: dispositivo de protección cerebral en TAVIDEFLECT I: dispositivo de protección cerebral en TAVI
DEFLECT I: dispositivo de protección cerebral en TAVI
 
POLAR ACS: plataforma bio absorbible en síndromes coronarios agudos
POLAR ACS: plataforma bio absorbible en síndromes coronarios agudosPOLAR ACS: plataforma bio absorbible en síndromes coronarios agudos
POLAR ACS: plataforma bio absorbible en síndromes coronarios agudos
 
ELISA 3: estrategia invasiva precoz vs tardía en pacientes sin supra desnivel...
ELISA 3: estrategia invasiva precoz vs tardía en pacientes sin supra desnivel...ELISA 3: estrategia invasiva precoz vs tardía en pacientes sin supra desnivel...
ELISA 3: estrategia invasiva precoz vs tardía en pacientes sin supra desnivel...
 
THRIVE: La niacina / laropiprant de liberación prolongada. Beneficio cardiova...
THRIVE: La niacina / laropiprant de liberación prolongada. Beneficio cardiova...THRIVE: La niacina / laropiprant de liberación prolongada. Beneficio cardiova...
THRIVE: La niacina / laropiprant de liberación prolongada. Beneficio cardiova...
 
RELAX: Inhibidor de la fosfodiesterasa-5. Insuficiencia cardiaca con función ...
RELAX: Inhibidor de la fosfodiesterasa-5. Insuficiencia cardiaca con función ...RELAX: Inhibidor de la fosfodiesterasa-5. Insuficiencia cardiaca con función ...
RELAX: Inhibidor de la fosfodiesterasa-5. Insuficiencia cardiaca con función ...
 
Reestenosis intrastent farmacológico con balón farmacológico
Reestenosis intrastent farmacológico con balón farmacológico Reestenosis intrastent farmacológico con balón farmacológico
Reestenosis intrastent farmacológico con balón farmacológico
 
Stent liberador de sirolimus vs everolimus en bifurcaciones
Stent liberador de sirolimus vs everolimus en bifurcacionesStent liberador de sirolimus vs everolimus en bifurcaciones
Stent liberador de sirolimus vs everolimus en bifurcaciones
 
¿Qué métodos han confirmado su eficacia para prevenir la nefropatía inducida ...
¿Qué métodos han confirmado su eficacia para prevenir la nefropatía inducida ...¿Qué métodos han confirmado su eficacia para prevenir la nefropatía inducida ...
¿Qué métodos han confirmado su eficacia para prevenir la nefropatía inducida ...
 
BVS for BTK
BVS for BTKBVS for BTK
BVS for BTK
 
Antiplaquetarios en el síndrome coronario agudo
Antiplaquetarios en el síndrome coronario agudoAntiplaquetarios en el síndrome coronario agudo
Antiplaquetarios en el síndrome coronario agudo
 
Polymer-Free DES
Polymer-Free DESPolymer-Free DES
Polymer-Free DES
 
Drug-Eluting Stents for Multivessel PCI
Drug-Eluting Stents for Multivessel PCIDrug-Eluting Stents for Multivessel PCI
Drug-Eluting Stents for Multivessel PCI
 
The Effect of Timing of Stem Cell Delivery Following Acute Myocardial Infarct...
The Effect of Timing of Stem Cell Delivery Following Acute Myocardial Infarct...The Effect of Timing of Stem Cell Delivery Following Acute Myocardial Infarct...
The Effect of Timing of Stem Cell Delivery Following Acute Myocardial Infarct...
 
Pilot Trial of Two Levels of Hypothermia in Comatose Survivors from Out-of-Ho...
Pilot Trial of Two Levels of Hypothermia in Comatose Survivors from Out-of-Ho...Pilot Trial of Two Levels of Hypothermia in Comatose Survivors from Out-of-Ho...
Pilot Trial of Two Levels of Hypothermia in Comatose Survivors from Out-of-Ho...
 
Off-pump versus in-pump CABG in high-risk patients
Off-pump versus in-pump CABG in high-risk patientsOff-pump versus in-pump CABG in high-risk patients
Off-pump versus in-pump CABG in high-risk patients
 
Posible beneficio de la esplerenona en pacientes con infarto agudo de miocard...
Posible beneficio de la esplerenona en pacientes con infarto agudo de miocard...Posible beneficio de la esplerenona en pacientes con infarto agudo de miocard...
Posible beneficio de la esplerenona en pacientes con infarto agudo de miocard...
 
Cangrelor compared with clopidogrel improves efficiency without increasing bl...
Cangrelor compared with clopidogrel improves efficiency without increasing bl...Cangrelor compared with clopidogrel improves efficiency without increasing bl...
Cangrelor compared with clopidogrel improves efficiency without increasing bl...
 
Rosuvastatina disminuye la incidencia de nefropatía por contraste en paciente...
Rosuvastatina disminuye la incidencia de nefropatía por contraste en paciente...Rosuvastatina disminuye la incidencia de nefropatía por contraste en paciente...
Rosuvastatina disminuye la incidencia de nefropatía por contraste en paciente...
 

Recently uploaded

Physiology of Chemical Sensation of smell.pdf
Physiology of Chemical Sensation of smell.pdfPhysiology of Chemical Sensation of smell.pdf
Physiology of Chemical Sensation of smell.pdf
MedicoseAcademics
 
Pharma Pcd Franchise in Jharkhand - Yodley Lifesciences
Pharma Pcd Franchise in Jharkhand - Yodley LifesciencesPharma Pcd Franchise in Jharkhand - Yodley Lifesciences
Pharma Pcd Franchise in Jharkhand - Yodley Lifesciences
Yodley Lifesciences
 
Non-respiratory Functions of the Lungs.pdf
Non-respiratory Functions of the Lungs.pdfNon-respiratory Functions of the Lungs.pdf
Non-respiratory Functions of the Lungs.pdf
MedicoseAcademics
 
NVBDCP.pptx Nation vector borne disease control program
NVBDCP.pptx Nation vector borne disease control programNVBDCP.pptx Nation vector borne disease control program
NVBDCP.pptx Nation vector borne disease control program
Sapna Thakur
 
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Oleg Kshivets
 
Adv. biopharm. APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMS
Adv. biopharm. APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMSAdv. biopharm. APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMS
Adv. biopharm. APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMS
AkankshaAshtankar
 
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptxMaxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Dr. Rabia Inam Gandapore
 
Light House Retreats: Plant Medicine Retreat Europe
Light House Retreats: Plant Medicine Retreat EuropeLight House Retreats: Plant Medicine Retreat Europe
Light House Retreats: Plant Medicine Retreat Europe
Lighthouse Retreat
 
How to Give Better Lectures: Some Tips for Doctors
How to Give Better Lectures: Some Tips for DoctorsHow to Give Better Lectures: Some Tips for Doctors
How to Give Better Lectures: Some Tips for Doctors
LanceCatedral
 
Vision-1.pptx, Eye structure, basics of optics
Vision-1.pptx, Eye structure, basics of opticsVision-1.pptx, Eye structure, basics of optics
Vision-1.pptx, Eye structure, basics of optics
Sai Sailesh Kumar Goothy
 
micro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdfmicro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdf
Anurag Sharma
 
Ocular injury ppt Upendra pal optometrist upums saifai etawah
Ocular injury  ppt  Upendra pal  optometrist upums saifai etawahOcular injury  ppt  Upendra pal  optometrist upums saifai etawah
Ocular injury ppt Upendra pal optometrist upums saifai etawah
pal078100
 
BRACHYTHERAPY OVERVIEW AND APPLICATORS
BRACHYTHERAPY OVERVIEW  AND  APPLICATORSBRACHYTHERAPY OVERVIEW  AND  APPLICATORS
BRACHYTHERAPY OVERVIEW AND APPLICATORS
Krishan Murari
 
New Drug Discovery and Development .....
New Drug Discovery and Development .....New Drug Discovery and Development .....
New Drug Discovery and Development .....
NEHA GUPTA
 
Novas diretrizes da OMS para os cuidados perinatais de mais qualidade
Novas diretrizes da OMS para os cuidados perinatais de mais qualidadeNovas diretrizes da OMS para os cuidados perinatais de mais qualidade
Novas diretrizes da OMS para os cuidados perinatais de mais qualidade
Prof. Marcus Renato de Carvalho
 
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness JourneyTom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
greendigital
 
KDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologistsKDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologists
د.محمود نجيب
 
Knee anatomy and clinical tests 2024.pdf
Knee anatomy and clinical tests 2024.pdfKnee anatomy and clinical tests 2024.pdf
Knee anatomy and clinical tests 2024.pdf
vimalpl1234
 
Are There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdfAre There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdf
Little Cross Family Clinic
 
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTSARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
Dr. Vinay Pareek
 

Recently uploaded (20)

Physiology of Chemical Sensation of smell.pdf
Physiology of Chemical Sensation of smell.pdfPhysiology of Chemical Sensation of smell.pdf
Physiology of Chemical Sensation of smell.pdf
 
Pharma Pcd Franchise in Jharkhand - Yodley Lifesciences
Pharma Pcd Franchise in Jharkhand - Yodley LifesciencesPharma Pcd Franchise in Jharkhand - Yodley Lifesciences
Pharma Pcd Franchise in Jharkhand - Yodley Lifesciences
 
Non-respiratory Functions of the Lungs.pdf
Non-respiratory Functions of the Lungs.pdfNon-respiratory Functions of the Lungs.pdf
Non-respiratory Functions of the Lungs.pdf
 
NVBDCP.pptx Nation vector borne disease control program
NVBDCP.pptx Nation vector borne disease control programNVBDCP.pptx Nation vector borne disease control program
NVBDCP.pptx Nation vector borne disease control program
 
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
 
Adv. biopharm. APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMS
Adv. biopharm. APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMSAdv. biopharm. APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMS
Adv. biopharm. APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMS
 
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptxMaxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
 
Light House Retreats: Plant Medicine Retreat Europe
Light House Retreats: Plant Medicine Retreat EuropeLight House Retreats: Plant Medicine Retreat Europe
Light House Retreats: Plant Medicine Retreat Europe
 
How to Give Better Lectures: Some Tips for Doctors
How to Give Better Lectures: Some Tips for DoctorsHow to Give Better Lectures: Some Tips for Doctors
How to Give Better Lectures: Some Tips for Doctors
 
Vision-1.pptx, Eye structure, basics of optics
Vision-1.pptx, Eye structure, basics of opticsVision-1.pptx, Eye structure, basics of optics
Vision-1.pptx, Eye structure, basics of optics
 
micro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdfmicro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdf
 
Ocular injury ppt Upendra pal optometrist upums saifai etawah
Ocular injury  ppt  Upendra pal  optometrist upums saifai etawahOcular injury  ppt  Upendra pal  optometrist upums saifai etawah
Ocular injury ppt Upendra pal optometrist upums saifai etawah
 
BRACHYTHERAPY OVERVIEW AND APPLICATORS
BRACHYTHERAPY OVERVIEW  AND  APPLICATORSBRACHYTHERAPY OVERVIEW  AND  APPLICATORS
BRACHYTHERAPY OVERVIEW AND APPLICATORS
 
New Drug Discovery and Development .....
New Drug Discovery and Development .....New Drug Discovery and Development .....
New Drug Discovery and Development .....
 
Novas diretrizes da OMS para os cuidados perinatais de mais qualidade
Novas diretrizes da OMS para os cuidados perinatais de mais qualidadeNovas diretrizes da OMS para os cuidados perinatais de mais qualidade
Novas diretrizes da OMS para os cuidados perinatais de mais qualidade
 
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness JourneyTom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
 
KDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologistsKDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologists
 
Knee anatomy and clinical tests 2024.pdf
Knee anatomy and clinical tests 2024.pdfKnee anatomy and clinical tests 2024.pdf
Knee anatomy and clinical tests 2024.pdf
 
Are There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdfAre There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdf
 
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTSARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
 

Tromboaspiración: resistencia de la microcirculación

  • 1. The randomized physiologic assessment of thrombus aspiration in patients with ST-segment elevation myocardial infarction trial PATA-STEMI study Dejan Orlic, MD on behalf of PATA STEMI investigators Clinical center of Serbia Belgrade, Serbia
  • 2. Potential conflicts of interest Speaker's name: Dejan Orlic  I do not have any potential conflict of interest
  • 3. Background and aim • Routine thrombus aspiration is superior to conventional PPCI in terms of improved myocardial perfusion in patients with STEMI • However, myocardial perfusion after thrombus aspiration has not been evaluated by a quantitative, invasive method, such as determining the index of microcirculatory resistance (IMR) • Our aim was to assess impact of thrombus aspiration on myocardial perfusion assessed by IMR in patients presenting with first STEMI
  • 4. Method IMR= 63x0,20=12,6 U CV Tmn res= 12,9 % CV Tmn hyp= 7,9 % Rmyo= ∆P/F= Pd-Pv/1/Tmn F≈1/Tmn Pv≈0 mmHg IMR= Pd x Tmn Fearon WF, Circ 2003
  • 5. Per protocol analysis Manual thrombus aspiration Eliminate catheter Predilatation or Direct stenting Primary endpoint = significant decrease of IMR Patients with first STEMI ≤12h from onset of chest pain randomization 1:1 PATA STEMI – study design IMR Direct stenting or predilatation *Thrombus aspiration catheter did not cross the lesion site and did not aspirate thrombi. Crossover to predilatation* **TIMI 0 or 1, or residual thrombus grade 4, or multipli thrombi persisted after predilatation. Crossover to aspiration** Conventional PPCI group Thrombus Aspiration group Angio Wiring of IRA ST Rescue PCI Prior MI Prior CABG LMCA AV block CPR COPD
  • 6. Expected IMR in conventional PPCI* = 38±20 U Expected reduction by TA = 26% (28±20 U) Alfa error = 5%; Power 80% Sample size to detect difference 128 patients Sample size calculation *Fearon W et al., JACC, 2008
  • 7. PATA STEMI – patient flow RANDOMIZATION 1:1 Thrombus aspiration (N=60) Conventional PCI (N=62)Coronary wire Thrombus aspiration (N=66) Predilatation (N=30) Stent implantation (N=68) Direct stenting (N=58) PTCA (N=4) TA alone (N=4) IMR (N=76) IMR (N=52) Coronary angiography Stent implantation (N=51) Direct stenting (N=21) PTCA (N=1) Crossover to predilatation (N=0) Crossover to aspiration (N=10) Final angiogram N=128 ECG at 60 min N=128 Echo ≤24h N=127 and at 4 mo N=125 Gentle predilatation (N=6)
  • 8. Thrombus aspiration Conventional P value (N=76) (N=52) Clinical characteristics Age 59,0±11,0 59,9±11,2 0,88 Male 50 (64,9%) 38 (73,1%) 0,94 Body mass index 26,8±3,86 27,9±4,56 0,41 Diabetes 9 (11,8% ) 5 (9,6%) 0,78 Hypertension 39 (51,3%) 28 (53,8%) 0,86 Hypercholesterolemia 17 (22,9%) 14 (27,4%) 0,67 Total ischemic time, min 190 (140-300) 175 (120-260) 0,12 System delay*, min 100 (65-165) 105 (65-145) 0,62 Killip class II 4 (5,2%) 3 (3,9%) 0,5 Angiographic characteristics LAD 31 (40,8%) 22 (42,3%) 0,9 TIMI flow grade 0 or 1 60 (78,9%) 41 (78,8%) 1 2 9 (11,8%) 6 (11,5%) 1 3 7 (9,2%) 5 (9,6%) 1 Thrombus length 10.5±7.48 7.04±4.81 0,014 Baseline characteristics *time from the first medical contact to the first balloon inflation or aspiration.
  • 9. Thrombus aspiration Conventional P value (N=76) (N=52) Procedural characteristics Fluoroscopy time 13.2±7.76 8.9±5.00 0,005 GP IIbIIIa inhibitor 24 (31,6%) 10 (19,2%) 0,15 Stent implantation 68 (89,5%) 51 (98,1%) 0,08 Stent length, mm 21,2±5,4 21,5±5,1 0,72 TIMI flow grade after wire 0 or 1 39 (51,3%) 16 (30,8%) 0,029 2 17 (22,4%) 25 (48,1%) 0,004 3 20 (26,3%) 11 (21,1%) 0,54 TIMI after TA/predilatation 0 or 1 1 (1,4%) 2 (6,7%) 0,20 2 8 (10,8%) 2 (6,7%) 0,72 3 65 (87,8%) 26 (86,6%) 1 TIMI final 2 4 (5,3%) 2 (3,8%) 1 3 72 (94,7%) 50 (96,2%) 1 Periprocedural complications Distal embolizations* 11 (14,5%) 8 (15,4%) 0,9 Side branch occlusion 1 (1,3%) 4 (7,7%) 0,16 Procedural characteristics *3 pts with crossover had distal embolizations (10,5 vs 21,2, P=0,09).
  • 10. Primary endpoint index of microcirculatory resistance CV Tmn rest 15,3±8,9%; CV Tmn hyp 15,1±8,1% Intention-to-treat analysis: IMR 42,4±36,1 vs. 32,0±22,4 U, P=0,020 P=0,0082 RR 32% Per-protocol analysis Adjacent non-IRA IMR 22,0±11,2 U vs. contralateral non-IRA IMR 25,8±17,9 U, p=0,3
  • 11. 59.2 46.1 31.6 40.4 9.2 13.5 0% 20% 40% 60% 80% 100% 1 2 ST 70 ST 30-70 ST 30 21.1 30.8 36.8 42.3 42.1 26.9 0% 20% 40% 60% 80% 100% 1 2 MBG 0 or 1 MBG 2 MBG 3 . . Conventional PCI Thrombus aspiration Myocardial blush grade Resolution of ST-segment elevation Percent of patients Percent of patients MBG 0 or 1: RR 0,68 (95% CI 0,38 to 1,24; p=0,21) ST >70%: RR 1,28 (95% CI 0,91 to 1,82; p=0,16) Angiographic and ECG signs of myocardial reperfusion Histopathological examination confirmed successful thrombus aspiration in 90,8% of patients.
  • 12. Echocardiographic analysis LV ESV/BSA Ml/m2 LV EDV/BSA 31,531,2 33,9 30,3 62,0 60,8 70,8 68,0 P=0,062 10,6%↓ P=0,22 P<0,0001 P<0,0001 P=0,4 LV ESV (ml); LV EDV (ml); BSA (m²)
  • 13. Infarct size Median CK max U/L Median AUC CK 46 027 35 442 23%↓ P=0,039 24%↓ P=0,046 2414 1843 Con PPCI: IQR 114 – 7310 U/L TA: IQR 72 – 5765 U/L Con PPCI: IQR 5760 – 159135 U/L TA: IQR 1395 – 108222 U/L
  • 14. Echocardiographic analysis LV EF % WMSI 49,9 48,8 51,4 54,6 6,0%↑ P=0,19 P= 0,5 P<0,0001 1,43 1,47 1,30 1,42 8,5%↓ P=0,13 P=0,0019 P= 0,9 LV EF (%); LV WMSI = wall motion score index U
  • 15. Clinical FU at 9 months % MACCE rate at 9 months MACCE (death, reMI, stroke, CHF or TVR): Con PPCI 3 deaths (2 sudden deaths=stent thrombosis possible and 1 stroke). 1 reSTEMI (stent thrombosis definite, TVR), 3 CHF and 3 TVR. TA 1 death (sudden death), 1 reSTEMI, 1 CHF and 4 TVR (2 TLR). 19,6 9,2 P=0,092 13,5 3,9 P=0,045 1,9 1,3 5,8 1,3 1,9* 5,8 1,3 5,3 5,8 *1 patient had CVI and death; CHF=congestive heart failure
  • 16. Regression model on log-transformed IMR Thrombus aspiration is independent predictor of lower lMR (36,11 U; 95%CI 30,74-42,41 vs. 27,14 U; 95%CI 23,79-30,95, P=0.0076). 32% Parameter Estimate* 95% Lower Limit 95% Upper Limit p-value Aspiration vs. Con. PPCI 0,7515 0,610 0,926 0,0076 DBP 1,012 1,002 1,022 0,0166 CK max (per 1000 units) 1,0888 1,013 1,170 0,0213 Age 1,0169 1,008 1,026 0,0005 *Per increase of 1 unit of the covariate, the IMR increases with the estimate as a FACTOR
  • 17. Conclusion • Manual thrombus aspiration reduces microcirculatory resistance indicating improved myocardial perfusion compared to conventional PPCI in patients with STEMI. • At mid term clinical follow up, the rate of hard adverse cardiac events is lower in thrombus aspiration group compared to conventional PPCI group. • Further studies powered for clinical outcomes are needed to confirm significance of our findings.
  • 18. Cath Lab Staff Dejan Orlic Goran Stankovic Branko Belelsin Milan Dobric Milorad Zivkovic Miodrag Ostojic Study investigators Coronary physiology Dejan Orlic Miodrag Ostojic Branko Beleslin Milan Dobric ECG analysis Vladan Vukcevic Milorad Zivkovic Dejan Orlic Echo analysis Milorad Tesic Danijela Zamaklar Histopathologic analysis Milica Borovic Data monitoring and analysis Goran Stankovic Dejan Milasinovic Dejan Orlic Angiographic analysis Sinisa Stojkovic Vladan Vukcevic Milan Nedeljkovic Dejan Orlic SPECT Dragana Sobic- Saranovic Cardiology clinic, Institute for histology, Institute for nuclear medicine Clinical center of Serbia, School of medicine, University of Belgrade
  • 20. Echocardiographic analysis CSI volume 0,40 0,41 0,44 0,43 P=0,6 P=0,0082 P=0,0083 CSI = cardiac sphericity index
  • 21. IMR and MACCE rate % MACCE rate at 9 months 12,7 3,1 P=0,045 Median IMR 30,7 U 15,9 10,9 P=0,41
  • 22. • Consecutive patients aged > 18 years • First STEMI (≥ 2 mm of ST-segment elevation in ≥ 2 contiguous leads) • Total ischemic time <12h • Hemodynamic stability INCLUSION CRITERIA
  • 23. • Rescue PCI • Stent thrombosis • Prior CABG • CPC resuscitation • Advanced AV block • Severe COPD • Distal LMCA stenosis (non-IRA) EXCLUSION CRITERIA
  • 24. PATA STEMI Thrombus Aspiration N = 66 Conventional PCI N = 62 Crossover N = 10 Thrombus Aspiration N = 76 Conventional PCI N = 52 Crossover to aspiration: TIMI 0 or 1 after balloon inflation or thrombus >2 vessel diameter Primary Endpoint = significantly decreased index of microcirculatory resistance Patients with first STEMI ≤12h from onset of chest pain Randomization 1:1 Predilatation N = 6
  • 25. Background IMR= 63x0,20=12,6 U CV Tmn bas= 12,9 % CV Tmn hyp= 7,9 % Rmyo= ∆P/F= Pd-Pv/1/Tmn F≈1/Tmn Pv≈0 mmHg IMR= Pd x Tmn Tmean= 3 boluses of saline at room t injected into coronary artery during max hyperemia. Specific, reproducible measure of coronary microcirculatory status less subject to hemodynamic variation (changes in heart rate, blood pressure, and cardiac contractility).
  • 26. Primary endpoint • significant decrease of IMR End points Secondary endpoints • blush grade • ST-segment resolution • infarct size by enzyme release • LV remodeling indices by echo • MACCE rate at 9 months
  • 27. Cath Lab Staff Dejan Orlic Branko Belelsin Goran Stankovic Milan Dobric Milorad Zivkovic Study investigators Coronary physiology Dejan Orlic Branko Beleslin Milan Dobric ECG analysis Vladan Vukcevic Milorad Zivkovic Dejan Orlic Echo analysis Milorad Tesic Danijela Zamaklar Histopathologic analysis Milica Borovic Data monitoring and analysis Dejan Orlic Dejan Milasinovic Goran Stankovic Angiographic analysis Vladan Vukcevic Sinisa Stojkovic Milan Nedeljkovic Dejan Orlic SPECT Dragana Sobic- Saranovic Cardiology clinic, Institute for histology, Institute for nuclear medicine Clinical center of Serbia, School of medicine, University of Belgrade